Clinical Research Fellow
Julia is a clinical research fellow at the Jenner Institute, working in the Tuberculosis (TB) vaccine programme, headed by Professor Helen McShane.
Tuberculosis kills 1.8 million people each year and is becoming increasingly resistant to antibiotic therapy. As such there is an urgent need to develop an effective vaccine. The group is currently working on a Phase 1 trial assessing the safety and immunogenicity of a novel viral vector TB vaccine in adults with latent TB. We are also running a clinical trial using a novel challenge model to better understand the human immune response to Mycobacterial infection.
Julia’s background is a primary care physician with subspecialties in public health and tropical medicine. She has experience working in Kenya, Tanzania and Papua New Guinea and prior to coming to Oxford worked under Professor Heath in paediatric vaccine trials at St George’s, University of London.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults.
Riste M. et al, (2021), Vaccines, 9
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891